0746 GMT - Novartis's significant profit and sales beat could close the gap between its mid-term growth guidance that is clearly above market's expectations, Vontobel analyst Stefan Schneider says in a note. The Swiss pharma giant's key drugs overall exceeded consensus with heart drug Entresto its best-selling medicine, despite prostate-cancer drug Pluvicto being shy of consensus, the analyst says. "This quarterly (and annual) results add on to a continuous streak of results where Novartis beats their own and the market's expectations," he said. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 31, 2025 02:46 ET (07:46 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。